35 results about "Urine cotinine level" patented technology

The prevent invention relates to an integrated package-holder assay devices for detecting the presence of analyte in a sample. The device serves the dual roles of supporting and protecting an immunochromatographic assay. The device is compatible with any immunochromatographic assay format. The assay can be performed in a single apparatus for use in a laboratory or a field setting. In a specific example, the assay device is a nylon membrane formatted for an immunochromatographic assay for cotinine sealed between transparent adhesive tape and a stiff plastic strip. White tape placed over the plastic strip defined a window for observing the assay results.

The present invention relates to a multi portion intra-oral dosage form where at least one portion is rapidly disintegrating and at least one portion is slowly disintegrating, whereby the disintegration time for the slowest disintegrating portion is at least two times longer than for the most rapidly disintegrating portion. Of certain interest is use of sensory markers / signals as conceptual aids for the subject.,Also contemplated are a method and a system for delivering active agents, such as,nicotine and / or metabolites thereof, such as cotinine, nicotine N'-oxide, nornicotine, (S)-nicotine-N-ss-glucuronide and mixtures, isomers, salts and complexes thereof as well as use and production of said formulations.

Disclosed is a chewing gum composition capable of eliminating nicotine component from the body of a person chewing the chewing gum. Such a chewing gum composition functions to convert the nicotine produced in a human body after smoking to cotinine and to discharge the cotinine into urine. Accordingly, by chewing the chewing gum of the present invention, not only nicotine can be eliminated from the body, but also the incidence of cancer due to nicotine can be largely reduced.

The subject invention concerns materials and methods for treating and / or preventing diseases associated with accumulation of Aβ peptide in neural tissue. The subject invention also concerns materials and methods for treating and / or preventing stress disorders, such as post-traumatic stress disorder (PTSD). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of cotinine, or a pharmaceutically acceptable salt thereof, to a person or animal in need of treatment. The methods of the invention can be used to prevent and / or treat Alzheimer's disease, Parkinson's disease, and / or Down's syndrome. The subject invention also concerns compositions that comprise cotinine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or adjuvant.The subject invention concerns materials and methods for detecting and diagnosing conditions associated with accumulation of Aβ peptide in neural tissue, such as Alzheimer's disease and Parkinson's disease, using the chemical cotinine. In one embodiment, the method comprises administering cotinine labeled with a detectable label to a person or animal. The presence of labeled cotinine in neural tissue is then determined. The level and / or location of cotinine can be analyzed and a diagnosis made. The subject invention also concerns cotinine labeled with a detectable label. In one embodiment, the cotinine is labeled with a radioisotope that can be detected by Positron Emission Tomography (PET) or single photon emission computed tomography (SPECT).

The invention disclose a method for determining the content of cotinine in urine. The method comprises the following steps of: putting urine into a centrifugal tube, adding a deuterated internal standard and diluting with acetonitrile; placing the centrifugal tube in a vortex oscillation instrument, carrying out vortex oscillation and standing; sucking supernatant and filtering by an organic-phase filtering membrane, and obtaining filtrate to be determined; and preparing stock solution and working solution, and carrying out ultra-high-performance liquid chromatography-tandem mass spectrum determination. Compared with the traditional gas chromatography and mass spectrometry, the method has the beneficial effects that a mode of direct dilution with acetonitrile and vortex oscillation filtering sample injection is adopted, so that the pretreatment process is simplified and the analysis sensitivity is improved. The method has the advantages of simple operation, fastness, high accuracy and good sensitivity and repeatability.

A system for determining a level of Cotinine and Anabasine in a sample includes a test strip configured to receive a sample; and a meter configured to receive the test strip wherein the meter is configured to read the test strip and detect a level of Anabasine and Cotinine.

The invention provides a new strain of nicotine degrading bacteria—Pseudomonas ZUTSKD and its application. Pseudomonas sp. ZUTSKD (Pseudomonas sp. ZUTSKD), preserved in China Center for Type Culture Collection, date of preservation is June 18, 2007, preservation number CCTCCNO: M 207083. The bacteria can degrade nicotine to produce intermediate products such as 2,3'-Bipyridine, cotinine, 3-(3,4-dihydro-2H-pyrrol-5-yl)-Pyridine and 3-Pyridinecarboxylic acid, and can tolerate the highest nicotine With a concentration of 5.5g / L, it can degrade nicotine in waste tobacco powder, and has a certain application prospect in industry.

A method of inhibiting or treating chemotherapy-induced cognitive dysfunction comprising administering a therapeutically effective amount of cotinine to a cancer patient experiencing chemotherapy-induced cognitive dysfunction.

A method of improving specific immune response to small immunogens, haptens, has been developed by changing the linkage between the hapten and carrier being used for immunization. High affinity antibodies to cotinine have been produced using this method. Antibodies to a glycated protein have also been developed, utilizing an immunogen which is composed of a glycated peptide mimic of the glycated peptide sequence which is the target epitope, wherein the peptide mimic is constructed to conformationally mimic the conformation of the peptide in the native protein, the peptide mimic contains no charged groups or other immunodominant group, and is connected to a spacer sequence equivalent to a peptide spacer of between one and thirty amino acids in length, which serves to position the peptide epitope in a conformation that approximates its conformation in the native protein. In another embodiment, the peptide mimic and spacer are linked to a carrier molecule.

The present invention provides methods and compositions for treating acute and / or chronic inflammation with cotinine or a pharmaceutically acceptable salt thereof.

The invention discloses a method for determining the content of cotinine in urine, comprising the following steps: pipetting the urine into a centrifuge tube, adding a deuterated internal standard, and diluting with acetonitrile; placing the centrifuge tube in a vortex shaker, vortexing Shake and let stand; draw the supernatant and filter it through an organic phase filter membrane, and the filtrate is to be tested; prepare the stock solution and working solution, and use ultra-high performance liquid chromatography-tandem mass spectrometry for determination. Compared with the traditional gas chromatography-mass spectrometry method, the present invention adopts the method of direct dilution with acetonitrile and vortex vibration filtering for sample injection, which simplifies the pretreatment process and improves the analytical sensitivity. The method has the advantages of simple operation, rapidity, accuracy, good sensitivity and repeatability.